Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros




Base de datos
Intervalo de año de publicación
1.
Life (Basel) ; 14(5)2024 Apr 30.
Artículo en Inglés | MEDLINE | ID: mdl-38792603

RESUMEN

Porphyria denotes a heterogeneous group of metabolic disorders caused by anomalies in the biosynthesis of heme, a crucial component of hemoglobin and other vital hemoproteins [...].

2.
Mol Ther Oncol ; 32(1): 200772, 2024 Mar 21.
Artículo en Inglés | MEDLINE | ID: mdl-38596305

RESUMEN

Thanks to its very high genome-editing efficiency, CRISPR-Cas9 technology could be a promising anticancer weapon. Clinical trials using CRISPR-Cas9 nuclease to ex vivo edit and alter immune cells are ongoing. However, to date, this strategy still has not been applied in clinical practice to directly target cancer cells. Targeting a canonical metabolic pathway essential to good functioning of cells without potential escape would represent an attractive strategy. We propose to mimic a genetic metabolic disorder in cancer cells to weaken cancer cells, independent of their genomic abnormalities. Mutations affecting the heme biosynthesis pathway are responsible for porphyria, and most of them are characterized by an accumulation of toxic photoreactive porphyrins. This study aimed to mimic porphyria by using CRISPR-Cas9 to inactivate UROS, leading to porphyrin accumulation in a prostate cancer model. Prostate cancer is the leading cancer in men and has a high mortality rate despite therapeutic progress, with a primary tumor accessible to light. By combining light with gene therapy, we obtained high efficiency in vitro and in vivo, with considerable improvement in the survival of mice. Finally, we achieved the preclinical proof-of-principle of performing cancer CRISPR gene therapy.

3.
Mol Genet Metab Rep ; 39: 101076, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38601120

RESUMEN

Acute hepatic porphyrias are inherited metabolic disorders of heme biosynthesis characterized by the accumulation of toxic intermediate metabolites responsible for disabling acute neurovisceral attacks. Givosiran is a newly approved siRNA-based treatment of acute hepatic porphyria targeting the first and rate-limiting δ-aminolevulinic acid synthase 1 (ALAS1) enzyme of heme biosynthetic pathway. We described a 72-year old patient who presented with severe inaugural neurological form of acute intermittent porphyria evolving for several years which made her eligible for givosiran administration. On initiation of treatment, the patient developed a major hyperhomocysteinemia (>400 µmol/L) which necessitated to discontinue the siRNA-based therapy. A thorough metabolic analysis in the patient suggests that hyperhomocysteinemia could be attributed to a functional deficiency of cystathionine ß-synthase (CBS) enzyme induced by givosiran. Long-term treatment with vitamin B6, a cofactor of CBS, allowed to normalize homocysteinemia while givosiran treatment was maintained. We review the recently published cases of hyperhomocysteinemia in acute hepatic porphyria and its exacerbation under givosiran therapy. We also discuss the benefits of vitamin B6 supplementation in the light of hypothetic pathophysiological mechanisms responsible for hyperhomocysteinemia in these patients. Our results confirmed the importance of monitoring homocysteine metabolism and vitamin status in patients with acute intermittent porphyria in order to improve management by appropriate vitamin supplementation during givosiran treatment.

5.
J Equine Sci ; 35(1): 9-14, 2024 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-38524755

RESUMEN

A horse's body condition impacts every aspect of its life, including reproduction, performance, and health. Obesity and equine metabolic syndrome (EMS) are common in Nigeria; hence, early identification of a horse's obesity status by the owner is key to avoiding associated health issues such as EMS. Our study aimed to determine whether horse owners could effectively estimate their horses' body condition scores (BCSs) and cresty neck scores (CNSs). A total of 50 adult sedentary West African Barb horses owned by 50 different people were enrolled in the study. Body condition scores (BCSs) and cresty neck scores (CNSs) were assessed on scales of 1-9 and 0-5, respectively, by an experienced veterinarian and owners. The latter had no veterinary background, received no prior education, and assessed their horses based on provided visual aids and descriptions. The BCS estimates of the experienced veterinarian and owners were slightly in agreement (k=0.209), while there was moderate agreement (k=0.547) between the CNS estimates of the experienced veterinarian and the owners. The proportion of obesity based on the experienced veterinarian's estimation (32%) was higher than that of the owners (18%). The proportion of nuchal crest adiposity based on the experienced veterinarian's (38%) estimation was slightly lower than that of the owners (42%). A larger proportion of the owners underestimated their horses' BCSs and CNSs. We conclude that owners cannot effectively estimate their horses' BCSs and CNSs. It is imperative that they are informed about the health issues associated with obesity and are taught how to effectively estimate BCS and CNS.

6.
Life (Basel) ; 14(1)2024 Jan 17.
Artículo en Inglés | MEDLINE | ID: mdl-38255745

RESUMEN

(1) Background: Congenital erythropoietic porphyria (CEP), named Günther's disease, is a rare recessive type of porphyria, resulting from deficient uroporphyrinogen III synthase (UROS), the fourth enzyme of heme biosynthesis. The phenotype ranges from extremely severe perinatal onset, with life-threatening hemolytic anaemia, to mild or moderate cutaneous involvement in late-onset forms. This work reviewed the perinatal CEP cases recorded in France in order to analyse their various presentations and evolution. (2) Methods: Clinical and biological data were retrospectively collected through medical and published records. (3) Results: Twenty CEP cases, who presented with severe manifestations during perinatal period, were classified according to the main course of the disease: antenatal features, acute neonatal distress and postnatal diagnosis. Antenatal symptoms (seven patients) were mainly hydrops fetalis, hepatosplenomegaly, anemia, and malformations. Six of them died prematurely. Five babies showed acute neonatal distress, associated with severe anemia, thrombocytopenia, hepatosplenomegaly, liver dysfunction, and marked photosensitivity leading to diagnosis. The only two neonates who survived underwent hematopoietic stem cell transplantation (HSCT). Common features in post-natal diagnosis (eight patients) included hemolytic anemia, splenomegaly, skin sensitivity, and discoloured teeth and urine. All patients underwent HSCT, with success for six of them, but with fatal complications in two patients. The frequency of the missense variant named C73R is striking in antenatal and neonatal presentations, with 9/12 and 7/8 independent alleles, respectively. (4) Conclusions: The most recent cases in this series are remarkable, as they had a less fatal outcome than expected. Regular transfusions from the intrauterine period and early access to HSCT are the main objectives.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA